Thor Medical ASA - Asset Resilience Ratio
Thor Medical ASA (TRMED) has an Asset Resilience Ratio of 29.78% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Thor Medical ASA for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Thor Medical ASA's Asset Resilience Ratio has changed over time. See what is Thor Medical ASA's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Thor Medical ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Thor Medical ASA stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr123.39 Million | 29.78% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr123.39 Million | 29.78% |
Asset Resilience Insights
- Very High Liquidity: Thor Medical ASA maintains exceptional liquid asset reserves at 29.78% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Thor Medical ASA Industry Peers by Asset Resilience Ratio
Compare Thor Medical ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
|
Jade Biosciences, Inc.
NASDAQ:JBIO |
Biotechnology | 80.21% |
|
Theravance Biopharma Inc
F:0TB |
Biotechnology | 37.29% |
Annual Asset Resilience Ratio for Thor Medical ASA (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Thor Medical ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | Nkr1.00K ≈ $105.23 |
Nkr414.40 Million ≈ $43.61 Million |
-12.77pp |
| 2023-12-31 | 12.77% | Nkr42.25 Million ≈ $4.45 Million |
Nkr330.83 Million ≈ $34.81 Million |
-77.26pp |
| 2022-12-31 | 90.03% | Nkr98.72 Million ≈ $10.39 Million |
Nkr109.64 Million ≈ $11.54 Million |
-3.57pp |
| 2021-12-31 | 93.61% | Nkr277.71 Million ≈ $29.22 Million |
Nkr296.67 Million ≈ $31.22 Million |
+0.17pp |
| 2020-12-31 | 93.44% | Nkr293.98 Million ≈ $30.93 Million |
Nkr314.61 Million ≈ $33.11 Million |
-- |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.